VGKVanguard FTSE Europe ETF


$ 67.82 $ 0.84 (1.25 %)    

Wednesday, 03-Jul-2024 12:59:51 EDT
QQQ $ 490.95 $ 4.06 (0.83 %)
DIA $ 392.84 $ -0.46 (-0.12 %)
SPY $ 551.46 $ 2.45 (0.45 %)
TLT $ 91.86 $ 1.19 (1.31 %)
GLD $ 217.99 $ 2.43 (1.13 %)
$ 67.83
$ 67.61
$ 0.00 x 0
$ 0.00 x 0
$ 67.61 - $ 67.85
$ 53.54 - $ 69.61
1,701,471
na
na
$ 0.97
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://x.com/EpicNewsroom/status/1809179988131713090

 asia-in-red-uk-advances-as-labour-party-wins-majority-while-us-dollar-dips-ahead-of-payrolls-data---global-markets-today-while-us-slept

US stock markets closed mixed on July 3rd. S&P 500 and Nasdaq reached record highs, while Dow Jones fell. Asian markets als...

Core News & Articles

- Reuters Citing Politico

Core News & Articles

- Reuters Citing TV Stream

Core News & Articles

- Bloomberg

Core News & Articles

- Bloomberg

Core News & Articles

The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months ...

Core News & Articles

https://www.reuters.com/business/aerospace-defense/boeing-brief-european-regulators-new-production-plans-after-737-max-panel-20...

Core News & Articles

- Reuters Citing Sources

Core News & Articles

https://www.reuters.com/world/us/trump-reviews-plan-halt-us-military-aid-ukraine-unless-it-negotiates-peace-with-2024-06-25/Two...

Core News & Articles

Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3GAITHERSBURG, Md., Ju...

Core News & Articles

GSK Plc has lost out to Pfizer Inc. on a contract to supply millions of doses of its blockbuster RSV vaccine to the UK in a set...

Core News & Articles

https://ec.europa.eu/commission/presscorner/detail/en/ip_24_3433

Core News & Articles

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial− FRUZAQLA (fruquintinib) is the First Novel Targeted ...